合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 2025年3月15日上午，2025中国医学装备大会在重庆悦来国际会议中心成功召开。相关政府部门领导、知名院士、医疗机构专家，研发生产企业、高校、科 研院所、投融资机构负责人等嘉宾出席大会。 中国医学装备协会理事长 侯岩介绍， 2024年中国医学装备市场规模达到 1.35万亿 元，同比增长 6％ 左右 。据了解，目前我国已形成22个大类1100多个 品类的产品体系，是世界上产品类别和品种最齐全的国家之一，产品广泛服务于临床应用，覆盖卫生健康各个领域。 目前大会已圆满落幕。本届展会中，哪些企业凭借创新亮相引起了行业关注？又有哪些前沿产品和技术成为焦点？思宇将全面回顾展会精彩亮点，供各位读 者参考。 # 美敦力 美敦力在本届大会上展出 近80款 全球创新产品， 包括 全球首发的PulseSelect一次性心脏脉冲场消融导管 ，以及多款前沿技术产品， 其中不乏首次展出及近 期获批的产品和技术。 其中包括中国首款获批的 PulseSelect一次性心脏 ...

Industry Overview - The medical device industry is experiencing significant transformation in 2025, primarily driven by advancements in generative AI and agentic AI [1] - AI's role in optimizing workflows and improving patient care is becoming increasingly crucial due to a projected shortfall of 11 million health workers by 2030 [4] - Regulatory bodies are evolving to accommodate AI-enabled devices, with frameworks being developed to approve autonomous systems in healthcare, allowing for faster market entry of AI-powered medical devices while maintaining safety standards [5] Company Highlights - **NVIDIA**: The Clara platform enhances real-time medical imaging and predictive diagnostics, while BioNeMo advances drug discovery and biomarker identification [2] - **Resmed**: The company has a market cap of $34.8 billion and aims to improve 500 million lives through better residential healthcare by 2030, with a projected earnings growth rate of 22.7% in 2025 [9][8] - **GE HealthCare**: With a market cap of $39.03 billion, the company is focusing on AI and machine learning for clinical decision support and personalized therapies, expecting earnings growth of 4.7% in 2025 [11][10] - **Medtronic**: The company integrates AI across its portfolio, including systems for detecting colorectal polyps and adaptive deep brain stimulation, with a market cap of $119.6 billion and expected earnings growth of 5% in fiscal 2025 [14][13] Collaboration and Partnerships - MedTech companies are collaborating with AI leaders like Google Health and Microsoft to co-develop advanced solutions, accelerating AI integration across various medical applications [6] Market Dynamics - The shift towards outpatient procedures in areas like orthopedics and cardiology is driving demand for advanced imaging systems and interventional solutions [10] - AI-driven medical devices are becoming more adaptive, allowing for autonomous analysis of patient data and improved decision-making [3]

Group 1 - U.S. President Donald Trump announced a 25% tariff on imported goods from Mexico and Canada, and a doubling of tariffs on Chinese goods to 20% [1] - China retaliated by imposing its own tariffs on certain U.S. goods, sanctioning American companies, and planning to file a complaint with the World Trade Organization [1] - China banned imports of genetic sequencers from Illumina Inc [1] Group 2 - Goldman Sachs is optimistic about market stabilization and recovery in 2025, driven by rising demand and increased stimulus [2] - Analysts at Goldman Sachs see capital equipment markets at a turning point following a visit to China, emphasizing innovation as a key advantage [2] Group 3 - Goldman Sachs has upgraded GE Healthcare Inc from Neutral to Buy, raising the price target from $85 to $100 [3] - The analyst maintains a balanced view on GE Healthcare, projecting stable 4-5% growth in the base business, while facing headwinds in the China market [4] - The forecast for GE Healthcare's China sales is expected to return to 2023 levels by 2026, a revision from previous expectations of a rebound by 2028 [4] Group 4 - GE Healthcare stock was reported at $85.74, reflecting a 0.45% increase [5]

Core Insights - GE HealthCare Technologies Inc. (GEHC) has launched the Genesis portfolio, a cloud-based enterprise imaging software-as-a-service (SaaS) solution aimed at modernizing healthcare data management [1][4] - The Genesis portfolio is designed to address the increasing complexity of healthcare data and IT challenges, providing a flexible and cost-effective alternative to traditional on-premises solutions [2][6] - The launch is expected to drive recurring revenue through cloud-based services, enhancing GEHC's market position and creating a steady stream of subscription-based income [4][5] Company Developments - GEHC's market capitalization stands at $39.59 billion, and the company reported an earnings surprise of 15.1% in the last quarter [5] - The Genesis portfolio includes features such as secure cloud connectivity, reduced imaging data management burdens, vendor-neutral archiving, and AI-powered data migration [10] - Recent strategic moves include the unveiling of the Freelium platform for MR imaging and a partnership with Sutter Health to enhance imaging services [11][12] Market Performance - Following the Genesis announcement, GEHC shares closed flat at $85.36, with a 2.1% decline over the past six months compared to the industry's 5.2% growth [3] - The S&P 500 index increased by 4.6% during the same period [3] Industry Context - The healthcare sector is experiencing a shift towards digital and AI-driven solutions, necessitating scalable and secure systems for efficient patient data management [6][8] - The Genesis portfolio aims to streamline workflows and improve patient care by integrating various hospital IT systems and enhancing data accessibility [8][9]

Core Insights - The handheld multi-parameter monitoring devices market is experiencing significant growth driven by the demand for portable and real-time health monitoring solutions [2][3] - The market was valued at US$ 3.2 billion in 2024 and is projected to grow at a CAGR of 4.6%, reaching over US$ 5.3 billion by 2035 [2][3] Market Drivers - Increasing prevalence of chronic diseases such as cardiovascular diseases, diabetes, and respiratory disorders necessitates continuous monitoring [6] - The shift towards home healthcare and remote patient monitoring is fostering personalized and decentralized healthcare solutions [6] - Advancements in sensor and wearable technologies are leading to the development of lightweight, non-invasive, and AI-integrated monitoring systems [6] - The growing geriatric population demands easy-to-use, real-time health tracking solutions [6] - The integration of telemedicine and digital health is expanding the adoption of cloud-based and Bluetooth-enabled diagnostic tools [6] Competitive Landscape - Key players in the market include Abbott, Medtronic, Koninklijke Philips N.V., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., GE HealthCare, and NIHON KOHDEN CORPORATION [7][11] - Companies are focusing on investments in sensor technology, AI-based analytics, and wireless connectivity to enhance patient monitoring experiences [7] Market Segmentation - By application, the market share is distributed as follows: Hospital & Clinical Use (40%), Home Healthcare (30%), Emergency & Critical Care (20%), and Military & Remote Healthcare (10%) [13] - By region, North America holds 45% market share, followed by Europe at 30%, Asia-Pacific at 15%, and the Rest of the World at 10% [14] Future Outlook - Emerging opportunities include portable handheld monitors for hospitals and home care, wearable multi-parameter devices integrated with smart technology, and wireless devices enabling remote monitoring [15] - The market is characterized by rapid technological advancements and increasing investments in healthcare infrastructure [9][10]

Core Viewpoint - GE HealthCare Technologies Inc. (GEHC) has introduced Freelium, a next-generation sealed magnet platform aimed at transforming Magnetic Resonance (MR) imaging by using less than 1% of helium compared to traditional systems, thereby enhancing sustainability and accessibility in helium-scarce regions [1][6]. Group 1: Product Features and Benefits - Freelium utilizes intelligent magnet technology that supports AI-enabled solutions, featuring remote monitoring and automated recovery to ensure consistent performance and minimize downtime [2][8]. - The platform is designed to reduce operational costs without compromising performance, operating without additional cooling or power requirements, and includes intelligent sensor technology for remote monitoring [8]. - Freelium's environmentally friendly design aligns with GEHC's sustainability goals, having already saved approximately 3 million liters of helium through its innovative magnet technology [9]. Group 2: Market Impact and Financial Performance - Following the announcement of Freelium, GEHC shares closed flat at $87.35, with a 3% increase over the past six months, compared to the industry’s 7.5% growth and the S&P 500's 8.1% increase during the same period [3]. - The introduction of Freelium is expected to drive long-term stock growth by providing a sustainable and cost-efficient MR imaging solution, potentially increasing GEHC's market share and revenue in the medical imaging sector [4]. - GEHC currently has a market capitalization of $39.95 billion and reported an earnings surprise of 15.1% in the last quarter [5]. Group 3: Strategic Developments - GEHC has made strategic moves to enhance its imaging services and AI capabilities, including a partnership with Sutter Health to improve access to innovative imaging services [10]. - The company is advancing its AI-driven technologies, with recent submissions for FDA clearance and the introduction of new imaging systems aimed at improving diagnostic accuracy and workflow efficiency [11][12].

Group 1 - Zacks Premium offers various tools for investors, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1][2] - The Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, helping investors identify securities with high potential to outperform the market [2][3] Group 2 - Each stock receives a rating from A to F based on its value, growth, and momentum, with A being the highest score indicating a better chance of outperforming [3] - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, and Price/Sales [3][4] - The Growth Score focuses on a company's financial strength and future outlook, analyzing projected and historical earnings, sales, and cash flow [4] - The Momentum Score helps investors capitalize on price trends, using factors like one-week price change and monthly earnings estimate changes [5] Group 3 - The VGM Score combines all Style Scores, providing a comprehensive indicator for investors who utilize multiple investing styles [6] - The Zacks Rank employs earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7][8] Group 4 - Investors are encouraged to select stocks with Zacks Rank 1 or 2 and Style Scores of A or B to maximize returns [10] - Stocks with lower ranks, such as 4 (Sell) or 5 (Strong Sell), even with high Style Scores, may still face downward price trends [11] Group 5 - GE HealthCare Technologies Inc. is a leading provider of medical technology and digital solutions, formed on January 3, 2023, after a spin-off from General Electric [12] - GE HealthCare has a Zacks Rank of 3 (Hold) and a VGM Score of B, with a Value Style Score of B due to a forward P/E ratio of 19.39 [12][13] - The company has seen upward revisions in earnings estimates, with the Zacks Consensus Estimate increasing by $0.01 to $4.70 per share, and an average earnings surprise of 6.2% [13]

2025年2月13日，GE Healthcare（纳斯达克股票代码：GEHC）股价上涨，其2024年第四季度业绩超出调整后的每股收益（EPS）预期。截至13日下午交 易时段，GEHC的股价上涨 超过9% ，达到每股 93.79美元 。 GE医疗报告了 7.37亿美元 的利润，第四季度销售额达到 53.2亿美元 （约合388亿人民币） ，每股收益为1.57美元。 经过调整，剔除一次性项目后，每股 收益为1.45美元，比华尔街预期高出19美分。销售额几乎与预期持平，专家此前预测的收入为53.3亿美元。 | Revenues | Organic orders growth **(1) | Adjusted EBIT* and Adjusted EBIT margin* | Adjusted EPS* | Free cash flow* | | --- | --- | --- | --- | --- | | S5.3B | 6% YoY | S994M | SI 45 | S811M | | 2% Organic growth*14 | Book-to-Bill** | 18.7% Margin | +23% YoY ...

Core Insights - GE HealthCare reported fourth-quarter adjusted EPS of $1.45, an increase from $1.18 a year ago, surpassing the consensus estimate of $1.26 [1] - The company achieved sales of $5.32 billion, nearly matching the consensus of $5.33 billion, reflecting a 2% year-over-year growth on both reported and organic bases [1] - Revenue growth was primarily driven by Advanced Visualization Solutions (AVS) and Pharmaceutical Diagnostics (PDx), with notable strength in the U.S. market [1] Financial Performance - For 2024, GE HealthCare recorded revenues of $19.7 billion, a 1% increase year-over-year on both reported and organic bases [2] - Net income attributable to GE HealthCare rose to $720 million from $403 million a year ago, while Adjusted EBIT increased to $994 million from $837 million [3] - The total company book-to-bill ratio was 1.09 times, with total orders increasing by 6% organically year-over-year [2] Management Commentary - GE HealthCare President and CEO Peter Arduini expressed satisfaction with the strong momentum in orders, backlog, and book-to-bill ratios observed in the fourth quarter [4] - The company continues to experience revenue growth driven by demand in AVS and PDx, alongside robust margin expansion and earnings growth [4] Future Guidance - GE HealthCare provided guidance for 2025, factoring in the impact of recently implemented U.S. tariffs on products from China [4] - The company anticipates organic revenue growth of 2% to 3% year-over-year, with an expected adjusted EBIT margin of 16.7%-16.8% [6] - Adjusted EPS is projected to be between $4.61 and $4.75, compared to the consensus of $4.66, with free cash flow expected to be at least $1.75 billion [6] Stock Performance - GEHC stock experienced a rise of 9.01%, reaching $93.64 during the last check on Thursday [5]

Core Insights - GE HealthCare (GEHC) reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.45, exceeding the Zacks Consensus Estimate of $1.26 by 15.1%, and showing a year-over-year improvement of 22.9% [1] - The company's shares gained 0.7% in pre-market trading following the earnings report, with a 3% increase over the past six months compared to the industry's 12.8% growth [2] - Total revenues for the fourth quarter were $5.32 billion, a 2% year-over-year increase, although it missed the Zacks Consensus Estimate by 0.2% [3] Revenue Details - Revenues were driven by strong performance in the U.S. market across all segments, particularly in Advanced Visualization Solutions and Pharmaceutical Diagnostics [3] - For the full year 2024, GEHC reported revenues of $19.67 billion, reflecting a 1% year-over-year increase [4] Segment Performance - Imaging segment revenues were $2.39 billion, flat year-over-year, with segment EBIT at $302 million, up 19% [5] - Advanced Visualization Solutions generated revenues of $1.44 billion, a 4% year-over-year increase, with segment EBIT at $374 million, up 15% [7] - Patient Care Solutions revenues were $827 million, flat year-over-year, with segment EBIT down 4% to $106 million [7] - Pharmaceutical Diagnostics revenues totaled $646 million, up 9% year-over-year, with segment EBIT at $212 million, up 47% [7] Margins and Cash Flow - The net income margin improved to 13.5%, up 580 basis points from the prior year, attributed to productivity and pricing benefits [8] - Cumulative cash flow from operating activities at the end of the fourth quarter was $1.96 billion, down from $2.1 billion a year ago [8] Financial Position - GEHC ended the fourth quarter with cash, cash equivalents, and investments of $2.89 billion, down from $3.57 billion in the previous quarter [9] - Total assets decreased to $33.08 billion from $33.86 billion sequentially [9] 2025 Guidance - For 2025, GE HealthCare expects adjusted EPS in the range of $4.61-$4.75, indicating a year-over-year growth of 3-6% [10] - Revenues are anticipated to grow 2-3% organically, reflecting continued demand for its products and services [10]